Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.60 |
| ▸ | PI4KA | P42356 | 2/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.56 |
| ▸ | AHCY | P23526 | 3/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NSD3 | Q9BZ95 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554686 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL22855519 | 0.84 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23547672 | 0.84 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2554197 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16578129 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL886940 | 0.83 | ADORA2A (0.63) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25651308 | 0.82 | AHCY (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3421178 | 0.80 | ADORA2A (0.59) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL336404 | 0.79 | ADORA2A (0.65) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10878427 | 0.79 | ADORA2A (0.65) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6194391-B1 | CS-87 (TITLE COMPOUND) INDUCES A TRANSIENT MUTATION IN HIV-1 AT THE 70TH CODON OF THE REVERSE TRANSCRIPTASE REGION OF THE VIRUS; ADMINISTERING TO A HUMAN IN NEED OF THERAPY WITH A DRUG THAT INDUCES A MUTATION IN HIV-1 AT ANOTHER LOCATION | EMORY UNIVERSITY | 2001-02-27 | — | — | US | claimed |
| US-9861652-B2 | 2′ Fluoronucleosides | EMORY UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | EMORY UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| EP-1504014-B1 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | METABASIS THERAPEUTICS INC (US) | 2015-12-02 | — | — | EP | disclosed |
| US-9180138-B2 | 2′-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2223927-B1 | Salts of a phosphonic acid based prodrug of PMEA | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130157971-A1 | 2'-FLUORONUCLEOSIDES | SCHINAZI RAYMOND F (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130018018-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | Epiphany Biosciences ,Inc. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8222257-B2 | Phosphono-pent-2-en-1-yl nucleosides and analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2470194-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | Epiphany Biosciences Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-1124565-A1 | AZIDO DERIVATIVES OF BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-08-22 | — | — | EP | disclosed |
| US-20010009906-A1 | Use of 3'-azido-2' ,3' -dideoxyuridine | SCHINAZI RAYMOND F (US) | 2001-07-26 | — | — | US | disclosed |
| EP-1098887-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Novirio Pharmaceuticals Limited (KY) | 2001-05-16 | — | — | EP | disclosed |
| EP-1089741-A1 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | EMORY UNIVERSITY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000025799-A1 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999066936-A9 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | UNIV EMORY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0986375-A2 | USE OF MKC-442 IN COMBINATION WITH OTHER ANTIVIRAL AGENTS | Triangle Pharmaceuticals Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000003998-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999066936-A1 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | EMORY UNIVERSITY (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1998044913-A2 | COMPOSITIONS CONTAINING MKC-442 IN COMBINATION WITH OTHER ANTIVIRAL AGENTS | TRIANGLE PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009906-A1 | Use of 3'-azido-2' ,3' -dideoxyuridine | NSUN2, DUT, DUS2 | ADORA2A 199/4885ADORA1 212/4885PI4KA 1537/4885 |
| US-20130018018-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | PNP, TYMP, ENTPD5 | ADORA2A 726/4885ADORA1 1106/4885PI4KA 287/4885 |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | PNP, BCL3, NPC1 | ADORA2A 916/4885ADORA1 651/4885PI4KA 837/4885 |
| US-20130157971-A1 | 2'-FLUORONUCLEOSIDES | PNP, BCL3, FUBP3 | ADORA2A 729/4885ADORA1 533/4885PI4KA 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.